Revance Therapeutics | RVNC - 应收帐款人



应收帐款人 更改 日
AbbVie USD 12.77B 132M 2025-09
ALKERMES USD 334.02M 21.08M 2025-12
Bristol-Myers Squibb USD 14.62B 485M 2025-09
Cara Therapeutics USD 2.24M 2.26M 2025-03
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 19.46B 2.25B 2025-09
J&J USD 21.33B 3.72B 2025-12
Merck USD 12.12B 596M 2025-09
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
P&G USD 6.28B 208M 2025-12
Pacira USD 124.07M 8.8M 2025-12
Supernus Pharmaceuticals USD 187.8M 16.55M 2025-12